LOKOREGIONARNYE INTERVENTsIONNORADIOLOGIChESKIE TEKhNOLOGII V LEChENII GEPATOTsELLYuLYaRNOGO RAKA
- Authors: Dolgushin B.I1, Virshke E.R1, Kosyrev V.Y.1, Martynkov D.V1, Trofimov I.A1, Breder V.V1
-
Affiliations:
- Issue: No 1s (2012)
- Pages: 30-37
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279199
- ID: 279199
Cite item
Abstract
Full Text
About the authors
B. I Dolgushin
E. R Virshke
V. Yu Kosyrev
D. V Martynkov
I. A Trofimov
V. V Breder
References
- Kong W.T., Zhang W.W., Qiu Y.D., et al. Major complications after radiofrequency ablation for liver tumors: analysis of 255 patients. World J Gastroenterol 2009; 15: 2651-56.
- Livraghi T., Solbiati L., Meloni M.F., et al. Treatment of focal liver tumors with percutaneous radiofrequency ablation: complications encountered in a multicenter study. Radiology 2003; 226: 441-51.
- Lin S.M., Lin C.J., Lin C.C., et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology 2004; 127: 1714-23.
- Giorgio A., Tarantino L., de Stefano G., Coppola C., Ferraioli G. Complications after percutaneous saline-enhanced radiofrequency ablation of liver tumors: 3-year experience with 336 patients at a single center. AJR 2005; 184: 207-11.
- Llovet J.M., Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48: 20-37.
- Orlando A., Leandro G., Olivo M., et al. Radiofrequency thermal ablation vs percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009; 104: 514-24.
- Bouza C., Lypez-Cuadrado T., Alcozar R., et al. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol 2009; 11(9): 31.
- Lencioni R.A., Allgaier H.P., Cioni D., et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation vs percutaneous ethanol injection. Radiology 2003; 228: 235-40.
- Shiina S., Teratani T., Obi S., et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 122-30.
- Lin S.M., Lin C.J., Lin C.C., et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54: 1151-56.
- Brunello F., Veltri A., Crucci P. et al. Radio frequency ablation vs ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 2008; 43: 727-35.
- Brown D.B., Gould J.E., Gervais D.A., et al. Society of interventional radiology technology assessment committee and the international working group on image-guided tumor ablation transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc interv Radiol 2009; 20: 425-34.
- Lin D.Y., Liaw Y.F., Lee T.Y., et al. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma-a randomized controlled trial. Gastroenterology 1988; 94: 453-56.
- Pelletier G., Roche A., Ink O., et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181-84.
- Group d'Etude et de Traitment du Carcinome Heґpatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256-61.
- Bruix J., Llovet J.M., Castells A., et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27: 1578-83.
- Pelletier G., Ducreux M., Gay F., et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 1998; 29: 129-34.
- Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71.
- Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.
- Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-39.
- Marelli L., Stigliano R., Triantos C., et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc intervent Radiol 2007; 30(1): 6-25.
- Llovet J.M., Di Bisceglie A.M., Bruix J., et al. Panel of experts in HCC-design clinical trials design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer inst 2008; 100: 698-711.
- Varela M., Real M.I., Burrel M., et al. Chemoembolisation of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-81.
- Poon R.T., Tso W.K., Pang R.W., et al. A phase I/II trial of chemoembolisation for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007; 5: 1100-18.
- Vogl T.J., Lammer J., Lencioni R., Malagari K., et al. Liver, Gastrointestinal, and Cardiac Toxicity in intermediate Hepatocellular Carcinoma Treated With PRECiSiON TACE With Drug-Eluting Beads: Results From the PRECISION V. Randomized Trial. AJR 2011; 197: 562-70.
- Sadick M., Haas S., Loehr M., et al. Application of DC beads in hepatocellular carcinoma: clinical and radiological results of a drug delivery device for transcatheter superselective arterial embolization. Onkologie 2010; 33: 31-37.
- Lammer J., Malagari K., Vogl T., et al. On behalf of the PRECISION V investigators prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECiSiON V study. Cardiovasc intervent Radiol 2010; 33: 41-52.
- Castells A., Bruix J., Ayuso C., et al. Transarterial embolization for hepatocellular carcinoma antibiotic prophylaxis and clinical meaning of postembolization fever. J Hepatol 1995; 22: 410-15.
- Vogl T.G., Lee C., Lencioni R., et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. J Clin Oncol 2010; 28: 14660A.
- Ibrahim S.M., Lewandowski R.J., Sato K.T., et al. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol 2008; 14: 1664-69.
- Raoul J.L., Guyader D., Bretagne J.F., et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997; 26: 1156-61.
- Vente M.A., Wondergem M., van der Tweel I., et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured metaanalysis. Eur Radiol 2009; 19: 951-59.
- Salem R., Lewandowski R.J., Mulcahy M.F., et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64.
- Kulik LM., Carr B.I., Mulcahy M.F., et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47: 71-81.
- Sangro S., Carpanese L., Cianni R., et al. European multicenter evaluation of survival for patients with hepatocellular carcinoma (HCC) treated by radioembolization with 90y-labeled resin microspheres. J Clin Oncol 2010; 28: 4027A.
- Косырев В.Ю. Радиочастотная термоаблация в лечении злокачественных опухолей печени (показания, методология, результаты лечения). Автореферат дисс.. докт. мед. наук. Москва 2011.
- Виршке Э.Р., Трофимов И.А., Долгушин Б.И., Кукушкин А.В. Результаты артериальной химиоэмболизапции микросферами DC Bead с доксорубицином у больных с неоперабельным гепатоцеллюлярным раком / Сборник материалов V научно-практической конференции по интервенционной радиологии в онкологии. Москва, 2012. С. 87-8.
- Kagawa T., Koizumi J., Kojima S. et al. Transcatheter Arterial Chemoembolization Plus Radio frequency Ablation Therapy for Early Stage Hepatocellular Carcinoma. Cancer 2010; 116: 3638-44.
- Yamakado K., Nakatsuka A., Takaki H., et al. Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology 2008; 247: 260-66.
- Schoenleber S.J., Kurtz D.M., Talwalkar J.A., et al. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009; 100: 1385-92.
- Wang B., Xu H., Gao Z.Q., et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 2008; 49: 523-29.
- Song B.C., Chung Y.H., Kim J.A., et al. Association between insulin-like growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: a prospective study. Cancer 2001; 91: 2386-93.
- Strebel B.M., Dufour J.F. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther 2008; 8: 1743-49.
- Chung Y., Kim B., Chen C., et al. Study in Asia of the combination of transcatheter arterial chemoembolization (TACE) with sorafenib in patients with hepatocellular carcinoma (HCC) trial (START): second interim safety and efficacy analysis [abstract]. J Clin Oncol 2010; 28: abstract 4026.
- ClinicalTrials.gov. Chemoembolization with or without sorafenib tosylate in treating patients with liver cancer that cannot be removed by surgery. Updated November 11, 2010. Available at: http://www.clinicaltrials.gov/ct2/show/NCT010049 78?term=sora fenib+ecog+1208&rank=1.
- UK Clinical Research Network: Portfolio Database. TACE-2 - a randomized placebo-controlled, double blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC). Available at: http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=5347.
- Hoffmann K., Glimm H., Radeleff B., et al. Prospective, randomized, double-blind, multicenter, phase III clinical study on transarterial chemoembolization (TACE) combined with sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer 2008; 8: 349.
- Dhanasekaran R., Kooby D.A., Staley C.A., et al. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug-eluting beads (DEB) for unresectable hepatocellular carcinoma (HCC) [published online ahead of print March 8, 2010]. J Surg Oncol. doi: 10.1002/jso.21522.
- Malagari K., Pomoni M., Kelekis A., et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with Beadblock for hepatocellular carcinoma [published online ahead of print November 24, 2009]. Cardiovasc Intervent Radiol. doi: 10.1007/s00270-009-9750-0.
- Song M.J., Chun H.J., Song D.S. et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012 Jul 20. pii: S0168-8278(12)00583-1. doi: 10.1016/j.jhep.2012.07.017.
- Louis C., Dewas S., Mirabel X. et al. Stereotactic Radiotherapy of Hepatocellular Carcinoma: Preliminary Results. Technol Cancer Res Treat 2010; 5: 479-87.